Literature DB >> 3014000

Human retroviral env and gag polypeptides: serologic assays to measure infection.

S B Kanner, C Cheng-Mayer, R B Geffin, W P Parks, G A Beltz, L O Arthur, K P Samuel, T S Papas.   

Abstract

Humoral antiviral responses to human retrovirus infections identify persistently infected individuals and can be used to characterize virus-host interactions. Antibodies to native viral polypeptides have been reliably measured, although quantitation of env antibodies is difficult due to a lack of purified antigens. To quantitate antibodies to env antigens, bacterially expressed cloned env polypeptides from the transmembrane regions of human T lymphotropic virus types I and III were applied to nitrocellulose filters in an immunodot assay. A combination of the sensitivity of the Western blot procedure and the specificity of peptides from defined viral sequences was used to detect 49/49 HTLV-III/LAV-infected individuals previously defined as seropositive by radioimmunoprecipitation sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Of these HTLV-III/LAV envelope seropositive people, 22% lacked antibody to p24 in a radioimmunoassay. In contrast, the sensitivity of antibody detection to HTLV-I env antigens and p24 were comparable. Antibodies to HTLV-I and HTLV-III/LAV env transmembrane peptides were not cross-reactive. Levels of antibody to env antigens of both HTLV-I and HTLV-III/LAV persisted without change for at least 26 mo, suggesting that most infections represent stable virus-host interactions. The use of bacterially expressed env peptides offers a rapid serologic approach for distinguishing human retroviral infections and can be used to define immune responses to specific regions of the viral genome.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014000

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  HTLV-I antibody studies in villagers in East Sepik Province, Papua New Guinea.

Authors:  R C Sanders; A Levin; G Anian; I Webber; H Lee; P Swanson; A Diwan; R Desowitz; W A Blattner; M P Alpers
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

2.  Use of TrpE/Gag fusion proteins to characterize immunoreactive domains on the human immunodeficiency virus type 1 core protein.

Authors:  M G Windheuser; G E Tegtmeier; C Wood
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

Review 3.  Mapping of viral epitopes with prokaryotic expression products.

Authors:  J A Lenstra; J G Kusters; B A van der Zeijst
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

4.  Improvement of gelatin particle agglutination test for detection of anti-HTLV-I antibody.

Authors:  R Fujino; K Kawato; M Ikeda; H Miyakoshi; M Mizukoshi; J Imai
Journal:  Jpn J Cancer Res       Date:  1991-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.